Biotech Blueprint podcast

Hims Launches Compounded GLP-1 Pill, CVS Forces Biosimilars – This Week in Biotech #88

0:00
6:05
Reculer de 15 secondes
Avancer de 15 secondes

Compounded semaglutide draws FDA scrutiny as Novo Nordisk guides 2026 lower and Eli Lilly leans into a $50 Medicare copay (Jan 30-Feb 5, 2026).


Follow Biotech Blueprint at biotechblueprint.com.

D'autres épisodes de "Biotech Blueprint"